{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:53:16Z","timestamp":1791928396870,"version":"4.3.4"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["annalsofvascularsurgery.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Vascular Surgery"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.avsg.2023.11.024","type":"journal-article","created":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T11:20:55Z","timestamp":1703589655000},"page":"164-178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Robustness of Longitudinal Safety and Efficacy After Paclitaxel-Based Endovascular Therapy for Treatment of Femoro-Popliteal Artery Occlusive Disease: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1016","volume":"101","author":[{"given":"Mario","family":"D'Oria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9378-9754","authenticated-orcid":false,"given":"Davide","family":"Mastrorilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Secemsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian-Alexander","family":"Behrendt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Veraldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall","family":"DeMartino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Mani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Budtz-Lilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Scali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Saab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano","family":"Calvagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Mezzetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Ruaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Lepidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.avsg.2023.11.024_bib1","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s00270-014-0876-3","article-title":"Standards of practice for superficial femoral and popliteal artery angioplasty and stenting","volume":"37","author":"Katsanos","year":"2014","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.avsg.2023.11.024_bib2","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jvs.2014.01.041","article-title":"Bayesian network meta-analysis of nitinol stents, covered stents, drug-eluting stents, and drug-coated balloons in the femoropopliteal artery","volume":"59","author":"Katsanos","year":"2014","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.avsg.2023.11.024_bib3","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/eci.12407","article-title":"Local delivery of paclitaxel in the treatment of peripheral arterial disease","volume":"45","author":"Ng","year":"2015","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.avsg.2023.11.024_bib4","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1016\/j.ijcard.2013.06.081","article-title":"Paclitaxelcoated balloon or primary bare nitinol stent for revascularization of femoropopliteal artery: a meta-analysis of randomized trials versus uncoated balloon and an adjusted indirect comparison","volume":"168","author":"Fusaro","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.avsg.2023.11.024_bib5","first-page":"CD011319","article-title":"Drugeluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the lower limbs","volume":"2016","author":"Kayssi","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.avsg.2023.11.024_bib6","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1177\/1526602816671740","volume":"23","author":"Katsanos","year":"2016","journal-title":"J Endovasc Ther"},{"key":"10.1016\/j.avsg.2023.11.024_bib7","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1177\/1526602815626557","article-title":"Systematic review and meta-analysis of randomized controlled trials of paclitaxel-coated balloon angioplasty in the femoropopliteal arteries: role of paclitaxel dose and bioavailability","volume":"23","author":"Katsanos","year":"2016","journal-title":"J Endovasc Ther"},{"key":"10.1016\/j.avsg.2023.11.024_bib8","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jvs.2019.01.080","article-title":"Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease","volume":"70","author":"Caradu","year":"2019","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.avsg.2023.11.024_bib9","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011245","article-title":"Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials","volume":"7","author":"Katsanos","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.avsg.2023.11.024_bib10","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/1526602820904783","article-title":"Mortality after paclitaxel-coated device use in patients with chronic limb-threatening ischemia: a systematic review and meta-analysis of randomized controlled trials","volume":"27","author":"Dinh","year":"2020","journal-title":"J Endovasc Ther"},{"key":"10.1016\/j.avsg.2023.11.024_bib11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s42155-021-00255-1","article-title":"Paclitaxel and mortality in patients with claudication and de novo femoropopliteal lesions: a historical cohort study","volume":"4","author":"Gahide","year":"2021","journal-title":"CVIR Endovasc"},{"key":"10.1016\/j.avsg.2023.11.024_bib12","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.119.005755","article-title":"Fragility index in cardiovascular randomized controlled trials","volume":"12","author":"Khan","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.avsg.2023.11.024_bib13","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.12469","article-title":"Application of the reverse fragility index to statistically nonsignificant randomized clinical trial results","volume":"3","author":"Khan","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.avsg.2023.11.024_bib14","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jclinepi.2013.10.019","article-title":"The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility Index","volume":"67","author":"Walsh","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.avsg.2023.11.024_bib15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12874-017-0315-7","article-title":"Trial Sequential Analysis in systematic reviews with meta-analysis","volume":"17","author":"Wetterslev","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.avsg.2023.11.024_bib16","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jvs.2021.01.041","article-title":"Long-term safety and efficacy of angioplasty of femoropopliteal artery disease with drug-coated balloons from the AcoArt I trial","volume":"74","author":"Xu","year":"2021","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.avsg.2023.11.024_bib17","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/j.jcin.2018.07.041","article-title":"Drug-coated balloon angioplasty compared with uncoated balloons in the treatment of 200 Chinese patients with severe femoropopliteal lesions: 24-month results of AcoArt I","volume":"11","author":"Xu","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.avsg.2023.11.024_bib18","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jcin.2019.12.028","article-title":"A polymer-Free paclitaxel-eluting stent versus a bare-metal stent for de novo femoropopliteal lesions: the BATTLE trial","volume":"13","author":"Gou\u00ebffic","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.avsg.2023.11.024_bib19","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/1358863X20988360","article-title":"Microcrystalline paclitaxel-coated balloon for revascularization of femoropopliteal artery disease: three-year outcomes of the randomized BIOPAC trial","volume":"26","author":"Nowakowski","year":"2021","journal-title":"Vasc Med"},{"key":"10.1016\/j.avsg.2023.11.024_bib20","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1007\/s00270-018-1940-1","article-title":"Two-year clinical outcomes of the CONSEQUENT trial: can femoropopliteal lesions be treated with sustainable clinical results that are economically sound?","volume":"41","author":"Albrecht","year":"2018","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.avsg.2023.11.024_bib21","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1148\/radiol.2020191619","article-title":"Drug-coated balloon angioplasty of femoropopliteal lesions maintained superior efficacy over conventional balloon: 2-year results of the randomized EffPac trial","volume":"295","author":"Teichgr\u00e4ber","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.avsg.2023.11.024_bib22","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1016\/j.jcin.2018.08.034","article-title":"Sustainable antirestenosis effect with a low-dose drug-coated balloon: the ILLUMENATE European randomized clinical trial 2-year results","volume":"11","author":"Brodmann","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.avsg.2023.11.024_bib23","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.117.005891","article-title":"Treatment effect of drug-coated balloons is durable to 3 Years in the femoropopliteal arteries: long-term results of the IN.PACT SFA randomized trial","volume":"11","author":"Schneider","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.avsg.2023.11.024_bib24","first-page":"664","article-title":"Drug-coated balloon versus uncoated percutaneous transluminal angioplasty for the treatment of atherosclerotic lesions in the superficial femoral and proximal popliteal artery: 2-year results of the MDT-2113 SFA Japan randomized trial","volume":"93","author":"Iida","year":"2019","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.avsg.2023.11.024_bib25","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1161\/CIRCULATIONAHA.116.025329","article-title":"Randomized comparison of\u00a0paclitaxel-eluting balloon and stenting versus plain balloon plus stenting versus directional atherectomy for femoral artery disease (ISAR-STATH)","volume":"135","author":"Ott","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.avsg.2023.11.024_bib26","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jcin.2014.07.023","article-title":"Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial","volume":"8","author":"Tepe","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.avsg.2023.11.024_bib27","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.jacc.2015.09.063","article-title":"Durability of treatment effect using a drug-coated balloon for femoropopliteal lesions: 24-month results of IN.PACT SFA","volume":"66","author":"Laird","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.avsg.2023.11.024_bib28","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.115.016900","article-title":"Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the zilver PTX randomized trial [published correction appears in circulation. 2019 Feb 19;139(8):e42]","volume":"133","author":"Dake","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.avsg.2023.11.024_bib29","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006321","article-title":"ISAR-PEBIS (Paclitaxel-Eluting balloon versus conventional balloon angioplasty for in-stent restenosis of superficial femoral artery): a randomized trial","volume":"6","author":"Ott","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.avsg.2023.11.024_bib30","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1177\/1526602820948240","article-title":"Three-year results of the IN.PACT SFA Japan trial comparing drug-coated balloons with percutaneous transluminal angioplasty","volume":"27","author":"Soga","year":"2020","journal-title":"J Endovasc Ther"},{"key":"10.1016\/j.avsg.2023.11.024_bib31","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/j.jacc.2013.03.034","article-title":"Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies [published correction appears in J Am Coll Cardiol. 2013 Aug 13;62(7):666]","volume":"61","author":"Dake","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.avsg.2023.11.024_bib32","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ejvs.2019.12.034","article-title":"Editor's choice - long term survival after femoropopliteal artery revascularisation with paclitaxel coated devices: a propensity score matched cohort analysis","volume":"59","author":"Behrendt","year":"2020","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.avsg.2023.11.024_bib33","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1056\/NEJMoa2005206","article-title":"Mortality with paclitaxel-coated devices in peripheral artery disease","volume":"383","author":"Nordanstig","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.avsg.2023.11.024_bib34","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1177\/15266028211023505","article-title":"Mortality rates after paclitaxel-coated device use in patients with occlusive femoropopliteal disease: an updated systematic review and meta-analysis of randomized controlled trials","volume":"28","author":"Dinh","year":"2021","journal-title":"J Endovasc Ther"},{"key":"10.1016\/j.avsg.2023.11.024_bib35","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jvir.2021.03.537","article-title":"The rollercoaster of paclitaxel in the lower limbs and skeletons in the closet: an opinion review","volume":"32","author":"Katsanos","year":"2021","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.avsg.2023.11.024_bib36","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jvir.2019.11.015","article-title":"Risk of death and amputation with use of paclitaxel-coated balloons in the infrapopliteal arteries for treatment of critical limb ischemia: a systematic review and meta-analysis of randomized controlled trials","volume":"31","author":"Katsanos","year":"2020","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.avsg.2023.11.024_bib37","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1161\/CIRCULATIONAHA.119.044697","article-title":"Mortality and paclitaxel-coated devices: an individual patient data meta-analysis","volume":"141","author":"Rocha-Singh","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.avsg.2023.11.024_bib38","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/bjc.2013.725","article-title":"Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence","volume":"110","author":"Booth","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.avsg.2023.11.024_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2021.100250","article-title":"Improving the enrollment of women and racially\/ethnically diverse populations in cardiovascular clinical trials: an ASPC practice statement","volume":"8","author":"Michos","year":"2021","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.avsg.2023.11.024_bib40","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ejvs.2020.01.029","article-title":"The swinging pendulum of evidence: is there a reality behind results from randomised trials and real world data? Lessons learned from the paclitaxel debate","volume":"59","author":"Behrendt","year":"2020","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.avsg.2023.11.024_bib41","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1001\/jamasurg.2019.0567","article-title":"The fragility index-P values reimagined, flaws and all","volume":"154","author":"Acuna","year":"2019","journal-title":"JAMA Surg"},{"key":"10.1016\/j.avsg.2023.11.024_bib42","doi-asserted-by":"crossref","first-page":"20f13334","DOI":"10.4088\/JCP.20f13334","article-title":"The use and limitations of the fragility index in the interpretation of clinical trial findings","volume":"81","author":"Andrade","year":"2020","journal-title":"J Clin Psychiatry"}],"container-title":["Annals of Vascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890509623008658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890509623008658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:12:49Z","timestamp":1760188369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890509623008658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":42,"alternative-id":["S0890509623008658"],"URL":"https:\/\/doi.org\/10.1016\/j.avsg.2023.11.024","relation":{},"ISSN":["0890-5096"],"issn-type":[{"value":"0890-5096","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Robustness of Longitudinal Safety and Efficacy After Paclitaxel-Based Endovascular Therapy for Treatment of Femoro-Popliteal Artery Occlusive Disease: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials","name":"articletitle","label":"Article Title"},{"value":"Annals of Vascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.avsg.2023.11.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}